Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Net Cash Flow: 2022-2025

Historic Net Cash Flow for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $20.8 million.

  • Entrada Therapeutics' Net Cash Flow rose 119.41% to $20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.2 million, marking a year-over-year decrease of 41.77%. This contributed to the annual value of $33.6 million for FY2024, which is 49.74% up from last year.
  • Entrada Therapeutics' Net Cash Flow amounted to $20.8 million in Q3 2025, which was up 347.88% from $4.6 million recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' Net Cash Flow peaked at $182.5 million during Q1 2023, and registered a low of -$202.5 million during Q1 2022.
  • Moreover, its 3-year median value for Net Cash Flow was $4.6 million (2025), whereas its average is $4.4 million.
  • In the last 5 years, Entrada Therapeutics' Net Cash Flow surged by 292.79% in 2023 and then plummeted by 4,101.68% in 2025.
  • Entrada Therapeutics' Net Cash Flow (Quarterly) stood at -$8.2 million in 2022, then spiked by 292.79% to $15.7 million in 2023, then spiked by 47.34% to $23.2 million in 2024, then soared by 119.41% to $20.8 million in 2025.
  • Its Net Cash Flow stands at $20.8 million for Q3 2025, versus $4.6 million for Q2 2025 and -$33.4 million for Q1 2025.